Aravofloxacin

Aravofloxacin
Clinical data
Routes of
administration		Oral, IV
Identifiers
  • 7-[(3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid[1]
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23F2N3O4
Molar mass419.429 g·mol−1
3D model (JSmol)
  • Fc1c(c(OC)c2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N4C/C(=C(/F)CN)CCC4
  • InChI=InChI=1S/C21H23F2N3O4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)/b16-11+ ☒N
  • Key:VMKVDAAFMQKZJS-LFIBNONCSA-N ☒N

Aravofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.[2][3][4]

Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed.[5]

As of 2016, tests are ongoing.[6]

References

  1. ^ "CSID:9721013". ChemSpider. Retrieved Aug 30, 2012.
  2. ^ Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (July 2011). "JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains". Antimicrobial Agents and Chemotherapy. 55 (7): 3631–4. doi:10.1128/AAC.00162-11. PMC 3122438. PMID 21555765.
  3. ^ Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K (May 2010). "In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone". Antimicrobial Agents and Chemotherapy. 54 (5): 1955–64. doi:10.1128/AAC.01374-09. PMC 2863672. PMID 20176911.
  4. ^ Sellarès-Nadal J, Burgos J, Falcó V, Almirante B. Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence. J Exp Pharmacol. 2020 Nov 19;12:529-538. doi:10.2147/JEP.S259286 PMID 33239925
  5. ^ "Novel Fluoroquinolone (JNJ-Q2)". Furiex Pharmaceuticals.
  6. ^ Jones TM, Johnson SW, DiMondi VP, Wilson DT (2016). "Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections". Infection and Drug Resistance. 9: 119–28. doi:10.2147/IDR.S105620. PMC 4908938. PMID 27354817.


Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.